Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 685509 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jun 2018
Price :
$35
*
At a glance
- Drugs Avenciguat (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 08 Jun 2018 Status changed from recruiting to completed.
- 21 May 2018 Planned End Date changed from 31 May 2018 to 30 Jul 2018.
- 21 May 2018 Planned primary completion date changed from 31 May 2018 to 30 Jul 2018.